论文部分内容阅读
神经元特异性烯醇化酶(NSE)监测小细胞肺癌(SCLC)患者的潜在价值已被许多研究报告所证明,本研究目的在于明确NSE 能否用于SCLC 诊断并评价其作为预后指标的意义。在SCLC 确诊后取患者血清贮存于-20℃,用Pharmacia 放免分析后检测,每次做双份,2.6ng/ml作为检测界限,正常范围上限定为12.5ng/ml。测定SCLC 病人治疗前血清NSE 值,广泛性病变患者的中位NSE 值明显高于局限性病变患者(48ng/ml 比17ng/mlp<0.001),有1例广泛性病变的SCLC 病人NSE<12.5ng/ml,因为胸腔外疾患发生脑转移,所有6例NSE>200ng/ml 的患者发生较
The potential value of neuron-specific enolase (NSE) monitoring in patients with small cell lung cancer (SCLC) has been proven by many studies. The purpose of this study is to determine whether NSE can be used for SCLC diagnosis and evaluate its significance as a prognostic indicator. After SCLC diagnosis, the patient’s serum was stored at -20°C and assayed by Pharmacia radioimmunoassay. Each duplicate was performed with 2.6ng/ml as the detection limit, and the normal range was limited to 12.5ng/ml. Serum NSE values before treatment were measured in patients with SCLC. The median NSE values of patients with extensive lesions were significantly higher than those with localized lesions (48 ng/ml vs. 17 ng/ml p<0.001), and NSE <12.5 ng in patients with extensive SCLC. /ml, brain metastases occurred in extrapulmonary disorders and occurred in all 6 patients with NSE >200 ng/ml